{"release":"wpf-flagship-weight-management","version":"1.4.0","resultsSha256":"7015f8dd771509f9548e11fe120b65641159173a214b88ed02a6a90183b4538e","license":{"name":"Creative Commons Attribution 4.0 International","identifier":"CC-BY-4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"licenseScope":{"covered":["The stable result identifiers (resultId) and the WPF citation strings","WPF's classification of each study's design (kind)","WPF-written estimand summaries (estimand), the analysis-plan section pointers, and the study-specific limitations (limitations)","The field corrections and their basis notes, and the release changelog","The selection, arrangement and structure of the dataset, and its CSV, BibTeX and JSON renderings","WPF-authored verification records (verification): the locator descriptions, verification notes, automated-check descriptions and outcomes, the not-verified lists and WPF's paraphrased summary of the authors' stated limitations","The release metadata and checksum file"],"excluded":["The cited papers and their abstracts, figures and tables (publishers and authors)","Short quotations of third-party text inside verification records (quotedSourceText: registry outcome-measure titles and similar strings). They are marked as third-party","Third-party slide decks and other reproductions linked only as corroboration","ClinicalTrials.gov records, posted results, protocols and statistical analysis plans (linked, not redistributed)","Regulator documents and product labels","Bibliographic identifiers and reported numerical facts as stated by their sources","WPF branding, logos and names","WPF films, transcripts and website copy","WPF repository code"],"unclearAndExcluded":["Fields that closely restate source reports: population, comparator, endpoint, followUp, result, uncertainty, discontinuation, funder and trial names. Ownership of this wording is unresolved, so it is outside the licensed scope until the Owner decides otherwise."]},"suggestedAttribution":"World Peptide Foundation, \"WPF Flagship Weight Management\", version 1.4.0 (2026-11-14), https://www.worldpeptidefoundation.org/releases/wpf-flagship-weight-management/1.4.0/release.json. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Please indicate whether you made changes.","result":{"resultId":"step-1-weight-68w","candidateId":"semaglutide:4","kind":"separate_placebo_controlled","trial":"STEP 1 (double-blind)","agents":"Semaglutide 2.4 mg vs placebo, plus lifestyle intervention","pmid":"33567185","doi":"10.1056/NEJMoa2032183","registryId":"NCT03548935","population":"1,961 adults with BMI 30 or more (27 or more with a weight-related condition), without diabetes","comparator":"Placebo plus lifestyle intervention (2:1 randomization)","endpoint":"Percent change in body weight and weight reduction of at least 5% (coprimary)","followUp":"68 weeks","result":"-14.9% with semaglutide vs -2.4% with placebo; estimated difference -12.4 percentage points","uncertainty":"Difference 95% CI -13.4 to -11.5","discontinuation":"Primary estimand assessed effects regardless of treatment discontinuation or rescue interventions.","funder":"Novo Nordisk","registryResultsPosted":true,"registryMasking":"Quadruple","estimand":"Treatment-policy primary estimand: effects regardless of adherence and of other anti-obesity treatment or rescue (the publication abstract's wording is \"regardless of treatment discontinuation or rescue interventions\"). The displayed difference of -12.4 points (95% CI -13.4 to -11.5) matches the registry's ANCOVA treatment difference, the method the plan specifies for this estimand. The arm values -14.9% and -2.4% are verified in the abstract only; the registry posts different, observed means.","analysisPlan":{"title":"STEP 1 Statistical Analysis Plan (redacted, document dated 3 Jul 2020), ClinicalTrials.gov NCT03548935","url":"https://cdn.clinicaltrials.gov/large-docs/35/NCT03548935/SAP_003.pdf","sections":"§1.1.4 Estimands (primary estimand); §2.3.1 primary endpoint analysis"},"limitations":["Both arms also received a lifestyle intervention, so the effect is of semaglutide added to lifestyle support.","Enrolled adults without diabetes; not evidence for people with type 2 diabetes.","Funded by the manufacturer of semaglutide."],"citation":"STEP 1 (double-blind). Semaglutide 2.4 mg vs placebo, plus lifestyle intervention. Primary source: https://doi.org/10.1056/NEJMoa2032183 (PMID 33567185; NCT03548935). Cited from World Peptide Foundation, WPF Flagship Weight Management, version 1.4.0, result step-1-weight-68w. Versioned record: https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=step-1-weight-68w | Result link: https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#step-1-weight-68w","releaseVersion":"1.4.0","designLabel":"Separate placebo-controlled trial (not a head-to-head)","designExplanation":"This drug was compared with placebo in its own trial. Setting two trials side by side is an indirect comparison across different populations, durations and designs, so their percentages cannot be subtracted.","verification":{"verifiedOn":"2026-11-12","locators":[{"claim":"Mean change -14.9% (semaglutide) vs -2.4% (placebo); difference -12.4 percentage points (95% CI -13.4 to -11.5)","source":"PubMed abstract","role":"primary","locator":"Abstract, Results paragraph: reports the week-68 mean change for each arm, the estimated treatment difference with its 95% confidence interval, and P<0.001, among 1,961 randomized adults; the Methods sentence states that the primary estimand assessed effects regardless of treatment discontinuation or rescue interventions.","url":"https://pubmed.ncbi.nlm.nih.gov/33567185/#abstract","status":"matched","method":"scripted","checkId":"pubmed-step1"},{"claim":"Between-group treatment difference -12.4 and its 95% confidence interval -13.4 to -11.5","source":"ClinicalTrials.gov results","role":"primary","locator":"Record NCT03548935, Results tab, primary outcome measure 1 (change in body weight, percent, baseline to week 68), analysis row for the semaglutide 2.4 mg vs placebo comparison whose group description names the treatment policy estimand: ANCOVA treatment difference -12.44, two-sided 95% CI -13.37 to -11.51, P<.0001.","url":"https://clinicaltrials.gov/study/NCT03548935?tab=results#outcome-measures","status":"matched","method":"scripted","checkId":"ctgov-step1-difference","note":"Rounding to one decimal place (halves away from zero) turns the registry values into the displayed ones: -12.44 becomes -12.4, -13.37 becomes -13.4 and -11.51 becomes -11.5. The registry names this row by its estimand (treatment policy), not by an observation period. A second row (hypothetical estimand: -14.42, CI -15.29 to -13.55) exists and is not displayed.","quotedSourceText":["Change in Body Weight (%)","Treatment policy estimand"]},{"claim":"Arm values: the paper's modelled -14.9% and -2.4% are not the registry's observed means","source":"ClinicalTrials.gov results","role":"primary","locator":"Same outcome measure, results by observation period: the in-trial period posts -15.6 (semaglutide) and -2.8 (placebo); the on-treatment period posts -16.9 and -3.1. These are observed means with standard deviations.","url":"https://clinicaltrials.gov/study/NCT03548935?tab=results#outcome-measures","status":"different_value","method":"scripted","checkId":"ctgov-step1-arm-means","note":"The displayed -14.9% and -2.4% are the paper's modelled estimates and are verified in the abstract only. The registry does not say which observation-period figures belong to which analysis row, so pairing in-trial with the treatment policy row would be inferred, and WPF does not rely on that pairing.","quotedSourceText":["In-trial observation period","On-treatment observation period"]},{"claim":"Primary estimand: effects regardless of treatment discontinuation or rescue interventions","source":"Statistical analysis plan","role":"primary","locator":"Redacted SAP (document dated 3 Jul 2020): section 1.1.4 on estimands defines the primary estimand as a treatment policy estimand (regardless of adherence and of other anti-obesity therapy); section 2.3.1 on the primary endpoint describes the ANCOVA with multiple imputation from retrieved participants.","url":"https://cdn.clinicaltrials.gov/large-docs/35/NCT03548935/SAP_003.pdf","status":"matched","method":"document_read","note":"Section numbering inside this redacted SAP is irregular: the estimand subsections are numbered 1.1.1.3 and 1.1.1.4 under 1.1.4."},{"claim":"Table or figure in the published paper that shows the displayed numbers","source":"Publisher page","role":"primary","locator":"Publisher article page reached through the DOI 10.1056/NEJMoa2032183","url":"https://doi.org/10.1056/NEJMoa2032183","status":"not_read","method":"document_read","note":"An automated request to this address returned HTTP 403 on 2026-11-12, which shows the request was blocked; it does not show why. Europe PMC lists no open-access full text for this paper, and WPF has not established whether the article sits behind a paywall. No table or figure number is claimed."}],"unverified":["The table or figure in the published paper that shows these numbers: not located, because the publisher page could not be read.","Discontinuation rates for each arm: not read from the full text.","Which registry observation-period figures belong to which analysis row: the registry does not say.","The authors' own limitations and disclosure statements: not reviewed, because the full text could not be read."],"automatedChecks":[{"id":"pubmed-step1","what":"The abstract reports the displayed arm values, the difference, its confidence interval, the sample size and the estimand wording.","method":"Re-runnable script (scripts/verification/verify-weight-management-sources.mts): fetches the PubMed record and compares the extracted abstract with the displayed values.","outcome":"Passed on 2026-11-14","lastRun":"2026-11-14"},{"id":"ctgov-step1-difference","what":"The specific registry row (treatment policy estimand, semaglutide vs placebo, ANCOVA, two-sided 95% CI) reports a difference of -12.44 with bounds -13.37 and -11.51, and each rounds to the displayed -12.4, -13.4 and -11.5.","method":"Re-runnable script (scripts/verification/verify-weight-management-sources.mts): compares the estimate and both bounds of that single row numerically. The same function runs in the CI gate against a stored copy of the registry record, with a test where correct arm means and a wrong difference or bound must fail.","outcome":"Passed on 2026-11-14","lastRun":"2026-11-14"},{"id":"ctgov-step1-arm-means","what":"The registry posts observed arm means of -15.6/-2.8 (in-trial) and -16.9/-3.1 (on-treatment). This is a separate claim from the treatment difference and does not support the modelled -14.9% and -2.4%.","method":"Re-runnable script (scripts/verification/verify-weight-management-sources.mts): compares each posted arm value numerically.","outcome":"Passed on 2026-11-14","lastRun":"2026-11-14"}],"humanReview":"none recorded"},"versionedRecordUrl":"https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=step-1-weight-68w","analysisPlanUrl":"https://cdn.clinicaltrials.gov/large-docs/35/NCT03548935/SAP_003.pdf","analysisPlanSections":"§1.1.4 Estimands (primary estimand); §2.3.1 primary endpoint analysis","registryCheckedOn":"2026-11-11","detailUrl":"https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#step-1-weight-68w"}}